Ironwood Pharmaceuticals is rated Buy mainly due to its drug apraglutide, as its current cash flow from Linzess faces pressure from upcoming generic competition expected by 2029 and Medicare price cuts. Linzess revenues are largely committed to debt and taxes, limiting growth potential. The success of apraglutide depends on positive results from the STARS-2 trial and timely regulatory approval, with peak sales conservatively estimated at $456 million. The company's valuation offers only a modest premium over its market cap, making the trial outcome and capital allocation critical risks for investors to watch.
Ironwood Pharmaceuticals and its drug apraglutide are the focus here, with Pluang's health sector data providing context. Of 100 priced health-sector US stocks on Pluang, 52 rose and 38 fell today. Notable moves include RXRX at USD 4.47 with a -3.46% change and 79% sell order activity, BAX at USD 23.70 with a -2.71% change and 100% buy order activity, and HRTX at USD 0.34 with a +2.50% change and 54% sell order activity. These figures are as of Oct 07, 2026 18:11 WIB.
Lumentum, a maker of optical and photonic products, reported a record $1.01 billion revenue in Q4 fiscal 2026, up 109% year-over-year, with non-GAAP net income rising 267% to $326.3 million. The company also provided strong guidance for Q1 2027, expe...
Canary Capital's Canary XRP ETF (XRPC) has fallen 36.68% since its launch in November 2025, trading at $15.74 with a net asset value of $15.83 as of September 28, 2026. Despite the decline, the fund holds $372.9 million in net assets and charges a 0....
Osisko Gold Group is rated 'Buy' due to its recent $600 million note financing that secures funding through the first gold pour at its Cariboo project. The flagship Cariboo mine aims to produce 220,000 ounces of gold annually for five years with a st...
Pi Network has moved its Protocol 28 upgrade to the Testnet stage and scheduled the Mainnet rollout for October 16. Node operators are required to upgrade their software by October 13 to support the new protocol, which aims to reduce transaction dela...
HBAR, the native cryptocurrency of Hedera, was analyzed to be near a support level of $0.09 on October 7. However, historical trading data from October 6 shows the token closed at $0.1012, with a low of $0.1010 and a high of $0.1021, indicating no co...
